222 related articles for article (PubMed ID: 35635625)
1. Immunotherapy in AL Amyloidosis.
Zhang Y; Comenzo RL
Curr Treat Options Oncol; 2022 Jul; 23(7):1059-1071. PubMed ID: 35635625
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits.
Popkova T; Hajek R; Jelinek T
Br J Haematol; 2020 Apr; 189(2):228-238. PubMed ID: 32072615
[TBL] [Abstract][Full Text] [Related]
3. Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.
Palladini G; Milani P; Malavasi F; Merlini G
Cells; 2021 Mar; 10(3):. PubMed ID: 33806310
[TBL] [Abstract][Full Text] [Related]
4. Advancements and future trends of immunotherapy in light-chain amyloidosis.
Mahadevia H; Ponvilawan B; Sharma P; Al-Obaidi A; Qasim H; Koyi J; Anwer F; Raza S
Crit Rev Oncol Hematol; 2023 Mar; 183():103917. PubMed ID: 36696931
[TBL] [Abstract][Full Text] [Related]
5. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis.
Parrondo RD; Majeed U; Sher T
Br J Haematol; 2020 Dec; 191(5):673-681. PubMed ID: 32298469
[TBL] [Abstract][Full Text] [Related]
6. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
[TBL] [Abstract][Full Text] [Related]
7. Nonchemotherapy Treatment of Immunoglobulin Light Chain Amyloidosis.
Van Doren L; Lentzsch S
Acta Haematol; 2020; 143(4):373-380. PubMed ID: 32526750
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab for the treatment of AL amyloidosis.
Sidiqi MH; Gertz MA
Leuk Lymphoma; 2019 Feb; 60(2):295-301. PubMed ID: 30033840
[TBL] [Abstract][Full Text] [Related]
9. A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis.
Nuvolone M; Basset M; Palladini G
Expert Opin Drug Saf; 2021 Apr; 20(4):411-426. PubMed ID: 33583294
[TBL] [Abstract][Full Text] [Related]
10. Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside.
Basset M; Nuvolone M; Palladini G; Merlini G
Expert Rev Hematol; 2020 Sep; 13(9):1003-1015. PubMed ID: 32721177
[TBL] [Abstract][Full Text] [Related]
11. Management of AL amyloidosis in 2020.
Palladini G; Milani P; Merlini G
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
[TBL] [Abstract][Full Text] [Related]
12. A pharmacist's review of the treatment of systemic light chain amyloidosis.
Hughes DM; Staron A; Sanchorawala V
J Oncol Pharm Pract; 2021 Jan; 27(1):187-198. PubMed ID: 33028132
[TBL] [Abstract][Full Text] [Related]
13. [Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient].
Vial G; Lafargue A; Mercié P; Duffau P; Ribeiro E
Rev Med Interne; 2022 Nov; 43(11):673-676. PubMed ID: 35934598
[TBL] [Abstract][Full Text] [Related]
14. Immune Therapies in AL Amyloidosis-A Glimpse to the Future.
Haran A; Vaxman I; Gatt ME; Lebel E
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672686
[TBL] [Abstract][Full Text] [Related]
15. First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma.
Oliver-Caldes A; Jiménez R; Español-Rego M; Cibeira MT; Ortiz-Maldonado V; Quintana LF; Castillo P; Guijarro F; Tovar N; Montoro M; Benitez-Ribas D; Bataller A; González-Navarro EA; Cid J; Lozano M; Perez-Amill L; Martin-Antonio B; Mena MP; Moreno DF; Rodríguez-Lobato LG; Campistol JM; Calvo G; Bladé J; Rosiñol L; Juan M; Pascal M; Urbano-Ispizua A; Fernández de Larrea C
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34876408
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies as an addition to current myeloma therapy strategies.
Jullien M; Touzeau C; Moreau P
Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750
[TBL] [Abstract][Full Text] [Related]
17. Supportive Care in AL Amyloidosis.
Cibeira MT; Ortiz-Pérez JT; Quintana LF; Fernádez de Larrea C; Tovar N; Bladé J
Acta Haematol; 2020; 143(4):335-342. PubMed ID: 32235118
[TBL] [Abstract][Full Text] [Related]
18. Management of AL amyloidosis in 2020.
Palladini G; Milani P; Merlini G
Blood; 2020 Dec; 136(23):2620-2627. PubMed ID: 33270858
[TBL] [Abstract][Full Text] [Related]
19. Future Developments in Light Chain Amyloidosis Management.
Rodriguez M; Lenihan D; Merlini G
Am J Med; 2022 Apr; 135 Suppl 1():S53-S57. PubMed ID: 35081388
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
